Gregory L Beatty

List of Publications by Year in Descending Order

64 papers	8,446 citations	38 h-index	66 g-index
66 ext. papers	10,086 ext. citations	10.4 avg, IF	6.31 L-index

#	Paper	IF	Citations
64	Systemic inflammation is a determinant of outcomes of CD40 agonist-based therapy in pancreatic cancer patients. *JCI Insight*, **2021**, 6,	9.9	3
63	The biological underpinnings of therapeutic resistance in pancreatic cancer. *Genes and Development* , **2021**, 35, 940-962	12.6	13
62	TNF blockade uncouples toxicity from antitumor efficacy induced with CD40 chemoimmunotherapy. *JCI Insight*, **2021**, 6,	9.9	1
61	Serum Amyloid A Proteins and Their Impact on Metastasis and Immune Biology in Cancer. *Cancers*, **2021**, 13,	6.6	2
60	A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma. *Molecular Cancer Therapeutics*, **2021**, 20, 389-397	6.1	3
59	Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in , , or. *Journal of Clinical Oncology*, **2021**, 39, 2497-2505	2.3	34
58	Inflammatory networks cultivate cancer cell metastasis to the liver. *Cell Cycle*, **2020**, 19, 642-651	4.7	5
57	Paracrine and cell autonomous signalling in pancreatic cancer progression and metastasis. *EBioMedicine*, **2020**, 53, 102662	8.8	19
56	Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle. *Seminars in Cancer Biology*, **2020**, 65, 38-50	12.7	17
55	The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance. *Journal of Leukocyte Biology*, **2020**, 108, 363-376	6.5	19
54	Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. *British Journal of Cancer*, **2020**, 122, 333-339	8.7	60
53	Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. *Molecular Therapy*, **2020**, 28, 2367-2378	11.7	13
52	Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis. *Journal of Experimental Medicine*, **2020**, 217,	16.6	44
51	Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47-mediated 'don't-eat-me' signal. *Nature Immunology*, **2019**, 20, 265-275	19.1	99
50	Cellular determinants and therapeutic implications of inflammation in pancreatic cancer. *Pharmacology & Therapeutics*, **2019**, 201, 202-213	13.9	29
49	Hepatocytes direct the formation of a pro-metastatic niche in the liver. *Nature*, **2019**, 567, 249-252	50.4	131
48	Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. *Gastroenterology*, **2019**, 156, 2056-2072	13.3	151

47	A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus -Paclitaxel and Gemcitabine in Advanced Solid Tumors. *Oncologist*, **2019**, 24, 14-e10	5.7	18
46	Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. *Molecular Therapy*, **2019**, 27, 1919-1929	11.7	101
45	Hepatocytes prepare the soil for liver metastasis. *Molecular and Cellular Oncology*, **2019**, 6, e1632686	1.2	2
44	Pancreas Cancer-Associated Weight Loss. *Oncologist*, **2019**, 24, 691-701	5.7	56
43	Macrophages: Key orchestrators of a tumor microenvironment defined by therapeutic resistance. *Molecular Immunology*, **2019**, 110, 3-12	4.3	27
42	Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. *Gastroenterology*, **2018**, 155, 29-32	13.3	209
41	CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients. *JCI Insight* , **2018**, 3,	9.9	40
40	Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma. *Clinical Cancer Research*, **2017**, 23, 137-148	12.9	164
39	Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. *Gut*, **2017**, 66, 124-136	19.2	178
38	IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma. *Molecular Cancer Therapeutics*, **2017**, 16, 1898-1908	6.1	63
37	Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. *Expert Review of Anticancer Therapy*, **2017**, 17, 175-186	3.5	74
36	First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. *Clinical Cancer Research*, **2017**, 23, 3269-3276	12.9	191
35	Functio Laesa: Cancer Inflammation and Therapeutic Resistance. *Journal of Oncology Practice*, **2017**, 13, 173-180	3.1	11
34	CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer. *Cancer Immunology, Immunotherapy*, **2017**, 66, 1609-1617	7.4	51
33	Deploying Immunotherapy in Pancreatic Cancer: Defining Mechanisms of Response and Resistance. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 267-278	7.1	21
32	Deploying Immunotherapy in Pancreatic Cancer: Defining Mechanisms of Response and Resistance. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 267-278	7.1	14
31	Expanding Tumor Lymphocytic Infiltration as a Prognostic Tool to Patients with NSCLC Who Are Treated with Radiotherapy?. *Journal of Thoracic Oncology*, **2016**, 11, e141-e142	8.9	
30	IFN and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma. *Cancer Discovery*, **2016**, 6, 400-413	24.4	137

29	Overcoming Therapeutic Resistance by Targeting Cancer Inflammation. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 35, e168-73	7.1	5
28	Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery. *Current Protocols in Pharmacology*, **2016**, 73, 14.39.1-14.39.20	4.1	88
27	Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps. *Pharmacology & Therapeutics*, **2016**, 166, 30-9	13.9	81
26	Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages. *Gastroenterology*, **2015**, 149, 201-10	13.3	182
25	Immune escape mechanisms as a guide for cancer immunotherapy. *Clinical Cancer Research*, **2015**, 21, 687-92	12.9	523
24	Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers **2015**,		16
23	Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. *Cancer Immunology Research*, **2014**, 2, 112-20	12.5	558
22	Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma. *OncoImmunology*, **2014**, 3, e28327	7.2	9
21	Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment. *OncoImmunology*, **2014**, 3, e970027	7.2	53
20	CD40 immunotherapy for pancreatic cancer. *Cancer Immunology, Immunotherapy*, **2013**, 62, 949-54	7.4	77
19	Macrophage-based immunotherapy for the treatment of pancreatic ductal adenocarcinoma. *OncoImmunology*, **2013**, 2, e26837	7.2	6
18	A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. *Clinical Cancer Research*, **2013**, 19, 6286-95	12.9	321
17	Harnessing the antitumor potential of macrophages for cancer immunotherapy. *OncoImmunology*, **2013**, 2, e26860	7.2	67
16	T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. *Cancer Immunology Research*, **2013**, 1, 26-31	12.5	376
15	T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. *Cancer Immunology Research*, **2013**, 1, 26-31	12.5	94
14	EMT and dissemination precede pancreatic tumor formation. *Cell*, **2012**, 148, 349-61	56.2	1422
13	Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. *Cancer Cell*, **2012**, 21, 822-35	24.3	648
12	CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. *Science*, **2011**, 331, 1612-6	33.3	1177

11	Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantation. *Clinical Cancer Research*, **2009**, 15, 4944-53	12.9	47
10	Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. *Clinical Cancer Research*, **2009**, 15, 4277-87	12.9	38
9	Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. *Cancer Letters*, **2009**, 279, 1-7	9.9	121
8	Telomerase as a universal tumor antigen for cancer vaccines. *Expert Review of Vaccines*, **2008**, 7, 881-7	5.2	48
7	Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer. *Expert Review of Anticancer Therapy*, **2008**, 8, 683-8	3.5	9
6	Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. *Cancer Research*, **2007**, 67, 10546-55	10.1	79
5	Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. *Biology of Blood and Marrow Transplantation*, **2006**, 12, 1150-60	4.7	60
4	Tumor sensitivity to IFN-gamma is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors. *Cancer Immunology, Immunotherapy*, **2005**, 54, 477-88	7.4	27
3	Regulation of tumor growth by IFN-gamma in cancer immunotherapy. *Immunologic Research*, **2001**, 24, 201-10	4.3	76
2	IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. *Journal of Immunology*, **2001**, 166, 2276-82	5.3	151
1	IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. *Journal of Immunology*, **2000**, 165, 5502-8	5.3	86